Outcome Predictors in Prosthetic Joint Infections Validation of a risk stratification score for Prosthetic Joint Infections in 120 cases

被引:0
|
作者
Wimmer, Matthias D. [1 ]
Randau, Thomas M. [1 ]
Friedrich, Max J. [1 ]
Ploeger, Milena M. [1 ]
Schmolder, Jan [1 ]
Strauss, Andreas C. [1 ]
Pennekamp, Peter H. [1 ]
Vavken, Patrick [1 ,2 ,3 ,4 ]
Gravius, Sascha [1 ]
机构
[1] Univ Hosp Bonn, Dept Orthopaed & Trauma Surg, Sigmund Freud Str 15, D-53113 Bonn, Germany
[2] Alphaclin Zurich, Kraftstr 29, CH-8044 Zurich, Switzerland
[3] Harvard Med Sch, Childrens Hosp Boston, Div Orthopaed Surg, Boston, MA USA
[4] Harvard Sch Publ Hlth, Harvard Ctr Populat & Dev Studies, Boston, MA USA
来源
ACTA ORTHOPAEDICA BELGICA | 2016年 / 82卷 / 01期
关键词
infection; revision; resistance; score; risk factors; RESISTANT STAPHYLOCOCCUS-AUREUS; TOTAL HIP-ARTHROPLASTY; KNEE ARTHROPLASTY; STRATEGIES; MANAGEMENT;
D O I
暂无
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
Prosthetic joint infections are a major challenge in total joint arthroplasty, especially in times of accumulating drug resistancies. Even though predictive risk classifications are a widely accepted tool to define a suitable treatment protocol a classification is still missing considering the difficulty in treating the causative pathogen antibiotically. In this study, we present and evaluate a new predictive risk stratification for prosthetic joint infections in 120 cases, treated with a two-stage exchange. Treatment outcomes in 120 patients with proven prosthetic joint infections in hip and knee prostheses were regressed on time of infection, systemic risk factors, local risk factors and the difficulty in treating the causing pathogen. The main outcome variable was "definitely free of infection" after two years as published. Age, gender, and BMI were included as co-variables and analyzed in a logistic regression model. 66 male and 54 female patients, with a mean age at surgery of 68.3 years +/- 12.0 and a mean BMI of 26.05 +/- 6.21 were included in our survey and followed for 29.0 +/- 11.3 months. We found a significant association (p < 0.001) between our score and the outcome parameters evaluated. Age, gender and BMI did not show a significant association with the outcome. These results show that our score is an independent and reliable predictor for the cure rate in prosthetic joint infections in hip and knee prostheses treated within a two-stage exchange protocol. Our score illustrates, that there is a statistically significant, sizable decrease in cure rate with an increase in score. In patients with prosthetic joint infections the validation of a risk score may help to identify patients with local and systemic risk factors or with infectious organisms identified as "difficult to treat" prior to the treatment or the decision about the treatment concept. Thus, appropriate extra care should be considered and provided.
引用
收藏
页码:143 / 148
页数:6
相关论文
共 50 条
  • [41] Characteristics of Enterobacter cloacae prosthetic joint infections
    Bouige, A.
    Fourcade, C.
    Bicart-See, A.
    Felice, M. P.
    Gautie, L.
    Krin, G.
    Lourtet-Hascoet, J.
    Marlin, P.
    Giordano, G.
    Bonnet, E.
    MEDECINE ET MALADIES INFECTIEUSES, 2019, 49 (07): : 511 - 518
  • [42] Prosthetic joint infections-a need for consolidation?
    Witso, Eivind
    ACTA ORTHOPAEDICA, 2016, 87 (04) : 321 - 323
  • [43] Time trends in the aetiology of prosthetic joint infections: a multicentre cohort study
    Benito, N.
    Franco, M.
    Ribera, A.
    Soriano, A.
    Rodriguez-Pardo, D.
    Sorli, L.
    Fresco, G.
    Fernandez-Sampedro, M.
    Dolores del Toro, M.
    Guio, L.
    Sanchez-Rivas, E.
    Bahamonde, A.
    Riera, M.
    Esteban, J.
    Baraia-Etxaburu, J. M.
    Martinez-Alvarez, J.
    Jover-Saenz, A.
    Duenas, C.
    Ramos, A.
    Sobrino, B.
    Euba, G.
    Morata, L.
    Pigrau, C.
    Coll, P.
    Mur, I.
    Ariza, J.
    CLINICAL MICROBIOLOGY AND INFECTION, 2016, 22 (08) : 732.e1 - 732.e8
  • [44] A standardized interdisciplinary algorithm for the treatment of prosthetic joint infections OUTCOME IN A CENTRALIZED AND SPECIALIZED DEPARTMENT
    Karczewski, D.
    Winkler, T.
    Renz, N.
    Trampuz, A.
    Lieb, E.
    Perka, C.
    Mueller, M.
    BONE & JOINT JOURNAL, 2019, 101B (02): : 132 - 139
  • [45] Predictors of Reinfection in Prosthetic Joint Infections Following Two-Stage Reimplantation
    Hartman, Curtis W.
    Daubach, Eric C.
    Richard, Brian T.
    Lyden, Elizabeth R.
    Haider, Hani
    Kildow, Beau J.
    Konigsberg, Beau S.
    Garvin, Kevin L.
    JOURNAL OF ARTHROPLASTY, 2022, 37 (07): : S674 - S677
  • [46] Evaluation of an interdisciplinary therapy algorithm in patients with prosthetic joint infections
    Wimmer, Matthias D.
    Randau, Thomas M.
    Petersdorf, Sabine
    Pagenstert, Geert I.
    Weisskopf, Markus
    Wirtz, Dieter C.
    Gravius, Sascha
    INTERNATIONAL ORTHOPAEDICS, 2013, 37 (11) : 2271 - 2278
  • [47] Incidence of Prosthetic Joint Infections After Primary Knee Arthroplasty
    Jaemsen, Esa
    Varonen, Markku
    Huhtala, Heini
    Lehto, Matti U. K.
    Lumio, Jukka
    Konttinen, Yrjoe T.
    Moilanen, Teemu
    JOURNAL OF ARTHROPLASTY, 2010, 25 (01): : 87 - 92
  • [48] Treatment of Prosthetic Joint Infections: Validation of a Surgical Algorithm and Proposal of a Simplified Alternative
    Martel-Laferriere, Valerie
    Laflamme, Pierre
    Ghannoum, Marc
    Fernandes, Julio
    Di Iorio, Daniela
    Lavergne, Valery
    JOURNAL OF ARTHROPLASTY, 2013, 28 (03): : 395 - 400
  • [49] Outcome of patients with streptococcal prosthetic joint infections with special reference to rifampicin combinations
    E. Fiaux
    M. Titecat
    O. Robineau
    J. Lora-Tamayo
    Y. El Samad
    M. Etienne
    N. Frebourg
    N. Blondiaux
    B. Brunschweiler
    F. Dujardin
    E. Beltrand
    C. Loiez
    V. Cattoir
    J. P. Canarelli
    C. Hulet
    M. Valette
    S. Nguyen
    F. Caron
    H. Migaud
    E. Senneville
    BMC Infectious Diseases, 16
  • [50] Outcome of patients with streptococcal prosthetic joint infections with special reference to rifampicin combinations
    Fiaux, E.
    Titecat, M.
    Robineau, O.
    Lora-Tamayo, J.
    El Samad, Y.
    Etienne, M.
    Frebourg, N.
    Blondiaux, N.
    Brunschweiler, B.
    Dujardin, F.
    Beltrand, E.
    Loiez, C.
    Cattoir, V.
    Canarelli, J. P.
    Hulet, C.
    Valette, M.
    Nguyen, S.
    Caron, F.
    Migaud, H.
    Senneville, E.
    BMC INFECTIOUS DISEASES, 2016, 16